Adipose Derived Stem Cell Therapy
Market Regional Analysis
North America is expected to hold
a dominant position in the global Adipose
Derived Stem Cell Therapy Market and account the largest market share
during the forecast period, owing to high presence of key players in the
region, which are engaged in research & development activities and
implementing in-organic growth strategies such as acquisition and collaboration
to increase its market presence.
For instance, in December 2017,
Mesoblast Limited made exclusive license agreement with TiGenix NV, through
which Mesoblast granted TiGenix an exclusive access to certain of its patents
to support global commercialization of Cx601, adipose derived mesenchymal stem
cell product, for the local treatment of fistulae.
Adipose derived stem cells
(ADSCs) are stem cells derived from adipocytes, and can differentiate into
variety of cell types. ADSCs have multipotency similar to bone marrow
mesenchymal stem cells, thus ADSCs substitute for bone marrow as a source of
stem cells. Numerous manual and automatic stem cell separation procedures are
adopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flow
cytometry can also be used to isolate ADSCs from other stem cells within a cell
solution.
Adipose derived stem cells are
gaining appeal as a new cell source in regenerative medicine therapies as it
can be differentiated into a variety of different cell lineages. These stem
cells also have anti-apoptotic, anti-inflammatory, pro-angiogenic,
immunomodulatory, and anti-scarring properties, which enhances its
effectiveness.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2357
Adipose Derived Stem Cell Therapy
Market Drivers
High effectiveness of adipose derived
stem cell therapy in various medical and biotechnology research fields coupled
with growing research and development activities by various research
organizations is expected to boost the adoption of adipose-derived stem cell
therapy in the market during the forecast period. Adipose derived stem cells
(ADSCs) have various applications in medical and biomedical science field such
as treatment of diabetes; regeneration of tissues partially in osteogenic,
adipogenic, chondrogenic, and cardiovascular areas of medicine; bone
regeneration; fat reconstruction; and myocardial and cardiovascular
regeneration; among others.
For instance, in November 2018, a
peer-reviewed case study conducted using a stem cell processed by Celltex
Therapeutics Corporation, showed the improvement in disease findings following
systemic administration of autologous adipose derived mesenchymal stem cells
(MSCs).
Adipose Derived Stem Cell Therapy
Market Restraint
High cost associated with stem
cell processing, need of skilled professional for managing, preserving, and
scale-up of stem cell lines are the limiting factors, which are expected to
restrain the growth of the adipose derived stem cell therapy market during the
forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/adipose-derived-stem-cell-therapy-market-2357
For instance, Bioinformant— a
research firm engaged in stem cell research— released a data on November 2018,
on cost of stem cell therapy and various key factors impacting the cost of stem
cell therapy including types of stem cells used within procedure, number of treatment,
and the site of the clinic. The study findings reveal the cost of stem cell
therapy ranges between US$ 5,000-8,000 per patient, in some cases it may rise
as much as US$ 25,000 or more depending on the complexity of the procedure.
Adipose Derived Stem Cell Therapy
Market Key Players
Key players operating in the
global adipose derived stem cell therapy market include BioRestorative
Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori
Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells
Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc.,
Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among
others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2357
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment